Pharmagreen Biotech (PHBI) AI Stock Analysis

• Market Cap: $1.33M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: -47.07%
• EPS Growth: 42.86%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 663,645,750
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: -0.11
• Price to Book (P/B): -0.90
• Price to Sales (P/S): 812.27
• P/FCF Ratio: -98.62
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 956.57
• Enterprise Value/Gross Profit: -2.64K
• Enterprise Value/Ebitda: -8.63
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 26 Underperform
• Price Target: ―
• Action: N/A Date: 04/06/25
• Date: Action: N/A 04/06/25

Pharmagreen Biotech is struggling with severe financial difficulties, characterized by negative equity and persistent cash flow issues. The lack of technical analysis data and poor valuation metrics further underscore the challenges faced by the company. Without significant improvement in financial performance or favorable market conditions, the stock remains highly risky.

Positive Factors

Proprietary Technology

The use of proprietary technology like 'Chibafreen' provides a competitive edge by ensuring high-quality, disease-free plantlets, crucial for consistent crop yields in the cannabis industry.

Market Demand

The growing legal cannabis market and demand for high-quality plant materials present opportunities for revenue growth, supporting long-term business prospects.

B2B Model

A B2B model focused on commercial growers ensures a stable customer base and aligns with industry needs, enhancing revenue stability and growth potential.

Negative Factors

Negative Equity

Negative equity reflects financial instability, limiting the company's ability to secure financing and invest in growth, posing a risk to long-term operations.

Cash Flow Issues

Persistent negative cash flow indicates operational inefficiencies and financial strain, threatening the company's ability to sustain operations without external funding.

Profitability Challenges

Ongoing profitability issues, marked by negative income and margins, hinder the company's ability to reinvest in growth and improve financial health.

Pharmagreen Biotech Business Overview & Revenue Model

Company Description

Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada.

How the Company Makes Money

Pharmagreen Biotech generates revenue through the sale of tissue cultured starter plantlets to commercial cannabis growers. The company employs a B2B model, catering specifically to businesses that require high-quality and consistent plant materials for their cultivation needs. Additionally, Pharmagreen may engage in partnerships or collaborations with other companies in the biotechnology and cannabis sectors to expand its market reach and enhance its service offerings. Significant factors contributing to Pharmagreen's earnings include advancements in tissue culture technology, the expanding legal cannabis market, and the increasing demand for standardized, disease-free plant materials.

Pharmagreen Biotech Financial Statement Overview

Summary

Pharmagreen Biotech is facing significant financial challenges, with persistent losses and negative equity. The company's revenue is minimal compared to its liabilities, and cash flow issues persist, suggesting that without a substantial turnaround or external financing, the business may struggle to maintain operations.

Income Statement

The company has struggled with profitability, as evidenced by negative net income and EBIT margins in the TTM period. Revenue showed some growth over the periods but remains low. The gross profit margin is positive, indicating some efficiency in production, but it is overshadowed by substantial operating losses.

Balance Sheet

There is significant financial instability, characterized by negative stockholders' equity, which indicates more liabilities than assets. The debt-to-equity ratio is extremely high due to negative equity, highlighting high leverage and financial risk. The equity ratio is negative, further underlining the precarious financial position.

Cash Flow

Cash flows are negative, with free cash flow consistently in the red. The company has managed to secure some financing, but this has not translated into positive operating cash flow. The inability to generate positive cash flow from operations is a critical concern for sustainability.

Breakdown	TTM	Sep 2024	Dec 2023	Dec 2022	Dec 2021	Sep 2020
Income Statement
Total Revenue	1.80K	3.41K	3.00K	0.00	0.00	0.00
Gross Profit	-652.00	1.74K	-6.45K	0.00	-435.00K	-435.00K
EBITDA	-199.40K	-971.18K	26.36K	194.27K	-3.76M	-677.00K
Net Income	-234.38K	-1.00M	-569.00K	-875.00K	-4.53M	-2.44M
Balance Sheet
Total Assets	96.60K	97.68K	121.57K	208.97K	373.08K	266.25K
Cash, Cash Equivalents and Short-Term Investments	568.00	276.00	1.25K	8.02K	25.30K	12.20K
Total Debt	354.33K	356.24K	372.84K	338.59K	270.20K	714.55K
Total Liabilities	2.67M	3.23M	2.30M	2.03M	2.07M	3.20M
Stockholders Equity	-2.52M	-3.09M	-2.13M	-1.78M	-1.65M	-2.89M
Cash Flow
Free Cash Flow	-19.00K	-28.09K	-73.84K	-426.57K	-206.08K	-607.63K
Operating Cash Flow	-19.00K	-28.09K	-73.84K	-426.57K	-206.08K	-607.63K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	25.71K	28.55K	83.37K	313.71K	257.50K	562.62K

Pharmagreen Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADXN	51 Neutral	$9.10M	-0.93	-71.27%	―	-72.15%	-223.62%
BJDX	46 Neutral	$1.99M	-0.02	-126.20%	―	―	97.70%
MSPR	40 Underperform	$571.39K	―	―	―	-8.57%	-52.17%
PHBI	26 Underperform	$1.33M	―	―	―	-47.07%	42.86%